HSBC bullish on IQVIA, Zoetis, bluebird, Actinium; bearish on Gilead

Golden Bull Market and Bear Market Sign Battle on US Dollar Banknotes

asbe/iStock via Getty Images

HSBC initiated coverage of 11 US biopharma stocks this week, adding IQVIA, Zoetis, bluebird and Actinium Pharmaceuticals to its “buy” ratings list.

IQVIA (NYSE:IQV) and Zoetis (NYSE:ZTS) were labeled “quality growth” stocks, joining such well-known names as Eli Lilly (